Life Sciences, Biotechnology and Diagnostics Segment — Impairment Charges
Danaher Life Sciences, Biotechnology and Diagnostics Segment — Impairment Charges decreased by 100.0% to $0 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $15M to $0. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase in impairment charges signals that the company has identified a decline in the expected future cash flows or market value of its assets, often suggesting poor performance of past acquisitions or technological obsolescence. A decrease or absence of charges suggests that the segment's assets are performing in line with or exceeding their carrying value expectations.
Detailed definition
This metric represents the non-cash expense recognized when the carrying value of long-lived assets, such as goodwill, i...
Peer comparison
Peers in the life sciences and diagnostics sector typically report these charges periodically following large-scale M&A activity, with high-performing companies maintaining minimal impairment levels relative to their total asset base.
dhr_segment_life_sciences_biotechnology_and_diagnostics_segment_impairment_chargesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $35M | $0 | $0 | $222M | $43M | $15M | $32.5M | $432M | $32.5M | $101M | $32.5M | $14M | $32.5M | $0 |
| QoQ Change | — | — | — | — | — | -100.0% | — | — | -80.6% | -65.1% | +116.7% | >999% | -92.5% | +210.8% | -67.8% | -56.9% | +132.1% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | +22.9% | — | — | — | — | -54.5% | -85.4% | -67.4% | -24.4% | -100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's life sciences, biotechnology and diagnostics segment — impairment charges?
- Danaher (DHR) reported life sciences, biotechnology and diagnostics segment — impairment charges of $0 in Q1 2026.
- How has Danaher's life sciences, biotechnology and diagnostics segment — impairment charges changed year-over-year?
- Danaher's life sciences, biotechnology and diagnostics segment — impairment charges decreased by 100.0% year-over-year, from $15M to $0.
- What does life sciences, biotechnology and diagnostics segment — impairment charges mean?
- The amount of value written off from assets in the life sciences and diagnostics business because they are no longer worth as much as previously recorded.